Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 3504

1.

Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.

Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, Bogg J, Dickson R, Walley T.

Health Technol Assess. 2004 Jun;8(24):iii-x, 1-125. Review.

2.

The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.

Connock M, Frew E, Evans BW, Bryan S, Cummins C, Fry-Smith A, Li Wan Po A, Sandercock J.

Health Technol Assess. 2006 Mar;10(7):iii, ix-118. Review.

3.

Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.

Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, Douglas G, Muers M, Smith D, White J.

Health Technol Assess. 2001;5(26):1-149. Review.

4.

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. Review.

5.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

6.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

7.

Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.

Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, Bayliss S, Roberts T, Burls A.

Health Technol Assess. 2007 Feb;11(6):iii-iv, 1-85. Review.

8.

Coronary artery stents: a rapid systematic review and economic evaluation.

Hill R, Bagust A, Bakhai A, Dickson R, Dündar Y, Haycox A, Mujica Mota R, Reaney A, Roberts D, Williamson P, Walley T.

Health Technol Assess. 2004 Sep;8(35):iii-iv, 1-242. Review.

9.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

10.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

11.

Sleep complaints: Whenever possible, avoid the use of sleeping pills.

[No authors listed]

Prescrire Int. 2008 Oct;17(97):206-12.

PMID:
19536941
12.

Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model.

Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ.

CNS Drugs. 2007;21(4):319-34. Erratum in: CNS Drugs. 2006;21(5):405.

PMID:
17381185
13.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

14.

A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery.

Cranny G, Elliott R, Weatherly H, Chambers D, Hawkins N, Myers L, Sculpher M, Eastwood A.

Health Technol Assess. 2008 Jan;12(1):iii-iv, xi-xii, 1-147. Review.

15.

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS.

Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. Review.

16.

'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.

Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D.

Health Technol Assess. 2008 Feb;12(2):iii-iv, ix-xi, 1-135. Review.

17.

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.

Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. Review.

18.

Management of chronic insomnia in elderly persons.

Bain KT.

Am J Geriatr Pharmacother. 2006 Jun;4(2):168-92. Review.

PMID:
16860264
19.

Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.

Knight C, Hind D, Brewer N, Abbott V.

Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82. Review.

20.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905

Supplemental Content

Support Center